164 related articles for article (PubMed ID: 35213773)
1. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus.
Ge S; Chu M; Tang J; Kahwaji J; Karasyov A; Lovato D; Vo A; Choi J; Jordan SC; Zhang R; Toyoda M
Transpl Infect Dis; 2022 Apr; 24(2):e13805. PubMed ID: 35213773
[TBL] [Abstract][Full Text] [Related]
2. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
3. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.
Wojciechowski D; Chandran S; Webber A; Hirose R; Vincenti F
Transplant Proc; 2017 Oct; 49(8):1773-1778. PubMed ID: 28923623
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
Kosoku A; Iwai T; Uchida J
Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
[TBL] [Abstract][Full Text] [Related]
6. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.
Toyoda M; Shin BH; Ge S; Mirocha J; Thomas D; Chu M; Rodriguez E; Chao C; Petrosyan A; Galera OA; Vo A; Choi J; Peng A; Kahwaji J; Jordan SC
J Immunol Res; 2017; 2017():5672523. PubMed ID: 28265581
[TBL] [Abstract][Full Text] [Related]
7. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
8. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects.
Renner FC; Dietrich H; Bulut N; Celik D; Freitag E; Gaertner N; Karoui S; Mark J; Raatz C; Weimer R; Feustel A
Transplant Proc; 2013 May; 45(4):1608-10. PubMed ID: 23726630
[TBL] [Abstract][Full Text] [Related]
9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
10. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
Hauser IA; Marx S; Sommerer C; Suwelack B; Dragun D; Witzke O; Lehner F; Schiedel C; Porstner M; Thaiss F; Neudörfl C; Falk CS; Nashan B; Sester M
Eur J Immunol; 2021 Apr; 51(4):943-955. PubMed ID: 33306229
[TBL] [Abstract][Full Text] [Related]
11. CMV, EBV, JCV and BKV infection and outcome following kidney transplantation in children initiated on a corticosteroid-minimisation immunosuppressive regimen.
McCaffrey J; Bhute VJ; Shenoy M
Pediatr Nephrol; 2021 Oct; 36(10):3229-3240. PubMed ID: 33825043
[TBL] [Abstract][Full Text] [Related]
12. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score.
Almond CS; Sleeper LA; Rossano JW; Bock MJ; Pahl E; Auerbach S; Lal A; Hollander SA; Miyamoto SD; Castleberry C; Lee J; Barkoff LM; Gonzales S; Klein G; Daly KP
Am Heart J; 2023 Jun; 260():100-112. PubMed ID: 36828201
[TBL] [Abstract][Full Text] [Related]
13. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
14. EBV, CMV, and BK viral infections in pediatric kidney transplantation: Frequency, risk factors, treatment, and outcomes.
Levi S; Davidovits M; Alfandari H; Dagan A; Borovitz Y; Bilavsky E; Landau D; Haskin O
Pediatr Transplant; 2022 May; 26(3):e14199. PubMed ID: 34817112
[TBL] [Abstract][Full Text] [Related]
15. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
19. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
[TBL] [Abstract][Full Text] [Related]
20. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
